Personalised medicine in oncology: Questions for the next 20 years

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 448-449

  Blay, Jean Yves ^a,b   Lacombe, Denis ^b   Meunier, Françoise ^b   Stupp, Roger ^b,c  

^a CENTRE LÉON BÉRARD   (France)

^b EORTC DATA CENTER   (Belgium)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PRACTICE; GASTROINTESTINAL STROMAL TUMOR; HEALTH CARE SYSTEM; HISTOPATHOLOGY; HUMAN; LETTER; LUNG CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL;

FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84860496028     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70156-0     Document Type: Letter

References (8)

1. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009, 462:1005-1010.
2. Pao W, Chmielecki J Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10:760-774.
3. Casali PG, Blay JY Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(suppl 5):v98-102. on behalf of the ESMO/CONTICANET/EUROBONET Consensus Panel of Experts.
4. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71:6051-6060.
5. Blay JY A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev 2011, 37:373-384.
6. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
7. Paik S, Kim C, Wolmark N HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358:1409-1411.
8. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol 2010, 11:942-949. for the French Sarcoma Group.